<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="188459">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00640224</url>
  </required_header>
  <id_info>
    <org_study_id>0503013</org_study_id>
    <secondary_id>2K24HD001357</secondary_id>
    <nct_id>NCT00640224</nct_id>
  </id_info>
  <brief_title>Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study</brief_title>
  <official_title>Obesity, Insulin Resistance, and Bone Metabolism in Adolescents With PCOS: Effects of Insulin Sensitizers Versus Oral Contraceptives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to investigate the effects of 2 different treatments (drospirenone/ethinyl
      estradiol versus rosiglitazone) on insulin sensitivity and androgen levels, inflammatory
      markers, vascular markers and bone development in overweight adolescent females with
      polycystic ovary syndrome (PCOS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to:

      1) to compare effects of treatment with drospirenone/ethinyl estradiol (Yasmin)versus
      rosiglitazone (Avandia) on hyperandrogenism, insulin resistance/hyperinsulinemia, adrenal
      hyperresponsiveness, body composition, chronic inflammation, bone mass and turnover.

      OCPs are the first-line therapy for PCOS, however, they do not address the insulin
      resistance or the inflammation. Insulin sensitizers have been used successfully to treat
      PCOS but thiazolidinediones such as rosiglitazone have not been used in adolescents.
      Therefore we will investigate the effects of treatment with drospirenone/ethinyl estradiol
      versus rosiglitazone in overweight adolescents with PCOS. We will obtain comprehensive
      evaluations before and 6 months after randomization, to the respective treatment arms to
      determine the differences between the 2 treatment modalities.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the effects of 6 months of treatment with drospirenone/ethinyl estradiol versus rosiglitazone on insulin resistance.</measure>
    <time_frame>6 months</time_frame>
    <description>Insulin resistance will be assessed by the hyperinsulinemic-euglycemic clamp. In addition glucose tolerance will be assessed using an oral glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the effects of 6 months of treatment with drospirenone/ethinyl estradiol versus rosiglitazone on bone turnover</measure>
    <time_frame>6 months</time_frame>
    <description>DXA scans and bone turnover markers will be measured at baseline and at completion of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the effects of 6 months of treatment with drospirenone/ethinyl estradiol versus rosiglitazone on hyperandrogenism</measure>
    <time_frame>6 months</time_frame>
    <description>Hyperandrogenism will be assessed by measuring testosterone level, and the response to a cortrosyn stimulation test at baseline and at completion of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the effects of 6 months of treatment with drospirenone/ethinyl estradiol versus rosiglitazone on cardiovascular health and inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>Lipid profiles,cardiovascular markers, intima media thickness, pulse wave velocity, and coronary califications using an EBCT will bemeasured at baseline and at conclusion of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the markers of cardiovascular health and inflammation within the PCOS group to those in overweight females without PCOS and lean females without PCOS</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drospirenone/ethinyl estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight/Obese without PCOS</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Overweight adolescent females without PCOS to use as comparison of normal developmental changes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean without PCOS</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Lean healthy girls without PCOS to serve as controls for the cardiovascular markers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
    <description>4 mg daily for 6 months</description>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drospirenone/ethinyl estradiol</intervention_name>
    <description>1 tab (3mg/30mcg) daily for 6 months</description>
    <arm_group_label>Drospirenone/ethinyl estradiol</arm_group_label>
    <other_name>Yasmin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 10 - 20 years

          -  Pubertal level of Tanner stage III-V and menarchal

          -  BMI percentile for age and sex greater than or equal to 85%ile

        Exclusion Criteria:

          -  Oral medications for PCOS, or that have impact on bone (i.e. anti-epileptics)

          -  Presence of other diseases, systemic or psychiatric, or chronic medications which
             could interfere with endocrine function

          -  Established diagnosis of diabetes

          -  Prior bone surgery, prior osteoporotic fracture, or fracture in the past 12 months

          -  Prior thromboembolic event, such as a deep venous thrombosis or pulmonary embolism
             (PCOS subjects only)

          -  Vitamin D deficiency (&lt;10ng/mL)

          -  Hyperkalemia (K&gt;5.0 meq/L)

          -  Positive pregnancy test (serum)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silva Arslanian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tfayli H, Ulnach JW, Lee S, Sutton-Tyrrell K, Arslanian S. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors. J Clin Endocrinol Metab. 2011 May;96(5):1311-9. doi: 10.1210/jc.2010-2547. Epub 2011 Feb 16.</citation>
    <PMID>21325466</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 27, 2016</lastchanged_date>
  <firstreceived_date>March 18, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Silva Arslanian, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
